AbbVie (NYSE:ABBV) Shares Acquired Rep. Jared Moskowitz

Representative Jared Moskowitz (D-Florida) recently bought shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on May 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in AbbVie stock on April 7th. The trade occurred in the Representative's "MORGAN STANLEY ACTIVE ASSETS (1)" account.

Representative Jared Moskowitz also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Amgen NASDAQ: AMGN on 4/16/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Starbucks NASDAQ: SBUX on 4/10/2025.
• Sold $15,001 - $50,000 in shares of The Goldman Sachs Group NYSE: GS on 4/10/2025.
• Sold $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 4/10/2025.
• Purchased $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 4/7/2025.
• Purchased $1,001 - $15,000 in shares of Southern NYSE: SO on 4/7/2025.
• Purchased $1,001 - $15,000 in shares of Sherwin-Williams NYSE: SHW on 4/7/2025.
• Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 4/7/2025.
• Purchased $1,001 - $15,000 in shares of TJX Companies NYSE: TJX on 4/7/2025.

AbbVie Stock Down 1.1%

Shares of NYSE:ABBV traded down $2.12 on Tuesday, reaching $187.95. The company had a trading volume of 7,523,103 shares, compared to its average volume of 6,176,062. AbbVie Inc. has a twelve month low of $153.58 and a twelve month high of $218.66. The stock has a 50-day moving average price of $193.79 and a 200 day moving average price of $187.23. The stock has a market capitalization of $332.48 billion, a P/E ratio of 78.31, a P/E/G ratio of 1.62 and a beta of 0.56. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, topping analysts' consensus estimates of $2.40 by $0.06. AbbVie had a return on equity of 296.28% and a net margin of 7.59%. The company had revenue of $13.34 billion during the quarter, compared to analysts' expectations of $12.91 billion. During the same quarter in the previous year, the firm earned $2.31 earnings per share. The business's quarterly revenue was up 8.4% compared to the same quarter last year. On average, equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $1.64 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.49%. AbbVie's dividend payout ratio is currently 279.15%.

Institutional Trading of AbbVie

Several hedge funds have recently modified their holdings of ABBV. Norges Bank acquired a new position in AbbVie during the 4th quarter worth about $4,459,385,000. GAMMA Investing LLC lifted its holdings in AbbVie by 25,841.6% in the first quarter. GAMMA Investing LLC now owns 10,234,737 shares of the company's stock valued at $2,144,382,000 after buying an additional 10,195,284 shares during the period. Nuveen LLC acquired a new position in AbbVie in the first quarter valued at approximately $1,819,154,000. Raymond James Financial Inc. acquired a new position in shares of AbbVie during the 4th quarter worth about $1,190,951,000. Finally, FMR LLC raised its stake in AbbVie by 32.8% during the 4th quarter. FMR LLC now owns 18,097,375 shares of the company's stock worth $3,215,903,000 after buying an additional 4,466,971 shares during the period. Institutional investors and hedge funds own 70.23% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ABBV shares. Evercore ISI raised their target price on shares of AbbVie from $204.00 to $205.00 and gave the company an "outperform" rating in a research note on Monday, April 28th. Morgan Stanley upped their price target on AbbVie from $241.00 to $250.00 and gave the stock an "overweight" rating in a report on Monday, April 28th. Bank of America upped their price target on AbbVie from $200.00 to $223.00 and gave the stock a "neutral" rating in a report on Tuesday, March 4th. BNP Paribas upgraded AbbVie to a "hold" rating in a report on Thursday, May 8th. Finally, Guggenheim upped their price target on AbbVie from $214.00 to $216.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Seven analysts have rated the stock with a hold rating, eighteen have given a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat, AbbVie has an average rating of "Moderate Buy" and a consensus target price of $211.41.

Insider Buying and Selling

In related news, EVP Timothy J. Richmond sold 29,917 shares of the firm's stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $202.90, for a total value of $6,070,159.30. Following the completion of the sale, the executive vice president now directly owns 44,284 shares in the company, valued at approximately $8,985,223.60. This trade represents a 40.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 5,778 shares of the company's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $197.90, for a total transaction of $1,143,466.20. Following the completion of the transaction, the executive vice president now owns 22,381 shares in the company, valued at approximately $4,429,199.90. This represents a 20.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 113,471 shares of company stock valued at $23,426,451. 0.25% of the stock is owned by company insiders.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida's 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida's 23rd Congressional District. He declared candidacy for the 2026 election. Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor's degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz's career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.